Connect with us

COVID-19

Moderna’s COVID-19 vaccine was shown to be effective in adolescents aged 12-17 and showed no new or major safety problems in a clinical trial

Published

on

Provo, UT – According to the officials, it’s potentially setting the stage for a second vaccine for school-aged children to be authorized in July.

Officials say that it will submit the findings of its adolescent study to the U.S. Food and Drug Administration and other regulators for emergency use authorization in early June.

Most children with COVID-19 develop only mild symptoms or no symptoms.

But, they remain at risk of becoming seriously ill, and they can spread the virus. Widely vaccinating 12- to 18-year olds could allow U.S. schools and summer camps to relax masking and social distancing measures suggested by the CDC.

The researchers found no new safety issues. The most common side effects after the second dose were headache, fatigue, body aches and chills.

Advertisement

Trending